Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse

Predicting cancer patients’ response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoanti...

Full description

Saved in:
Bibliographic Details
Published in:Immunity (Cambridge, Mass.) Mass.), 2015-10, Vol.43 (4), p.631-633
Main Authors: Church, Sarah E., Galon, Jérôme
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - pharmacology
Antigens
Antigens, Neoplasm - genetics
Apoptosis
Biomarkers
Biomarkers, Pharmacological
Cancer
Chemokines
CTLA-4 Antigen - antagonists & inhibitors
Cytotoxicity
Female
Gene expression
Humans
Immune system
Immunotherapy
Lymphocytes
Male
Melanoma
Melanoma - drug therapy
Melanoma - genetics
Metastasis
Mutation
Peptides
Signatures
Skin Neoplasms - drug therapy
Skin Neoplasms - genetics
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Predicting cancer patients’ response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mutations, predicts patient responses to immunotherapy. Predicting cancer patients’ response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mutations, predicts patient responses to immunotherapy.
ISSN:1074-7613
1097-4180
DOI:10.1016/j.immuni.2015.10.004